Answers are grounded in this paper and cite their sources.
Tebentafusp is the first approved T cell receptor (TCR)-based bispecific therapy and prolongs survival in metastatic uveal melanoma by redirecting T cells against gp100/HLA-A*02:01-positive tumor cells. However, how tebentafusp reshapes immune-cell interactions within the tumor microenvironment remains incompletely understood. Here, using HLA-defined donor T cells, dendritic cells (DCs), and tumor cell models with distinct gp100 and HLA-A*02:01 expression profiles, we identify a DC-dependent mechanism that enhances tebentafusp-mediated T cell activation, cytokine production, and cytotoxicity. Across the tumor cell models, the magnitude of tebentafusp-mediated functional responses was closely associated with gp100 abundance and HLA-A*02:01 surface expression. This DC-dependent enhancement was not explained by conventional antigen presentation or the tested CD80/CD86 pathway and was not further enhanced by PD-1 or CTLA-4 blockade. Notably, following direct co-culture with gp100-positive, HLA-A*02:01-positive tumor cells, HLA-A*02:01-negative DCs displayed surface-bound tebentafusp and subsequently enabled tebentafusp-specific T cell activation despite the HLA mismatch. Transfer required gp100 and HLA-A*02:01 expression as well as direct cell–cell contact, consistent with functional DC cross-dressing. Together, these findings reveal a DC-mediated amplification mechanism that extends tebentafusp activity beyond direct tumor–T cell interactions and may shape immune redirection within the tumor microenvironment.
No takes yet. Share an insight, caveat, or question.
Wiesinger et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: